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Introduction: Cannabis remains the most used illegal substance across the globe, and negative outcomes and
disorders are common. A spotlight therefore falls on reductions in cannabis use in people with cannabis use
disorder. Current estimates of unassisted cessation or reduction in cannabis use rely on community surveys, and
few studies focus on individuals with disorder. A key interest of services and researchers is to estimate effect size
of reductions in consumption among treatment seekers who do not obtain treatment. Effects within waiting list
or information-only control conditions of randomised controlled trials offer an opportunity to study this question.
Method: This paper examines the extent of reductions in days of cannabis use in the control groups of randomised
controlled trials on treatment of cannabis use disorders. A systematic literature search was performed to identify
trials that reported days of cannabis use in the previous 30 (or equivalent).
Results: Since all but one of the eight identiﬁed studies had delayed treatment controls, results could only be
summarised across 2–4 months. Average weighted days of use in the previous 30 days fell from 24.5 to 19.9, and
a meta-analysis using a random effects model showed an average reduction of 0.442 SD. However, every study
had at least one signiﬁcant methodological issue.
Conclusions:While further high-quality data is needed to conﬁrm the observed effects, these results provide a
baseline from which researchers and practitioners can estimate the extent of change required to detect effects of
cannabis treatments in services or treatment trials.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Cannabis remains the most used illegal drug across the world, and
while rates of use are generally falling, the incidence of related harm
is rising internationally (United Nations Ofﬁce on Drugs and Crime,
2014). Australia has particularly high rates of use, with 35% of adults
reporting lifetime consumption, and 10% using it in the previous
12 months (Australian Institute of Health and Welfare, 2014).
However, 70–80% of cannabis users stop using it by their mid-
thirties (Chen & Kandel, 1998), and even over 5–6 years, substantial
rates of cessation or reduced consumption in adolescents or young
adults are seen (Kandel & Raveis, 1989; Pollard, Tucker, de la Haye,
Green, & Kennedy, 2014; Sussman & Dent, 2004). In common with
other substances, most successful cessation occurs without treatment
(Cunningham, 2000; Price, Risk, & Spitznagel, 2001). While these
changes are typically greatest among infrequent or non-problematic
users (Chen & Kandel, 1998), people with cannabis abuse ordical Innovation, 60 Musk Ave,
nagh).
. This is an open access article underdependence also have substantial rates of recovery. For example, an
analysis of data from Wave 1 of the National Epidemiologic Survey on
Alcohol and Related Conditions (Agosti & Levin, 2007) found that 81%
of people with lifetime cannabis dependence did not meet criteria
over the previous year.
While community samples can provide good estimates of the degree
and timing of recovery from cannabis use disorder, sample sizes need to
be large to provide accurate estimates of these rates. So, a study of 1228
adolescents (Perkonnigg et al., 1999) found only 12 with lifetime
cannabis dependence, and the resultant estimate of full remission
(32%) therefore had a substantial standard error (26%). Furthermore,
treatment trial researchers and services need estimates of remission in
treatment seekers.
A study of control groups in treatment studies provides fertile
ground for the estimation of changes in treatment seekers who do not
receive substantial assistance. These studies have several advantages:
high-quality trials typically have diagnostic interviews and other
assessments that are able to characterise the samples well, the nature
of treatments is standardised or tracked carefully, and substantial effort
is put into ensuring that follow-up assessments maximise retention
rates. While individual studies often have relatively small sample sizes
in their control group, meta-analytic methods provide an opportunitythe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 2
Mean days of cannabis use in the past 30 days, in control groups of treatment trials on
people with cannabis use disorders.
Study Baseline 2–4 months
N M SD N M SD
Stephens et al. (2000) 86 24.9 6.1 79 17.1 10.7
Litt et al. (2005)1 148 30.0 4.7 148 25.2 10.2
Walker et al. (2006)2 50 18.4 8.5 50 16.4 10.3
Stephens et al. (2007)3 64 26.0 8.2 64 24.6 8.2
Martin and Copeland (2008)4 20 18.5 10.5 20 18.2 10.5
Fischer et al. (2012) 32 23.9 6.1 32 23.1 6.9
Gates et al. (2012)5 81 23.9 6.3 61 13.4 12.2
Rooke et al. (2013) 119 20.8 8.7 58 14.1 8.8
Total N, weighted mean 600 24.5 512 19.9
Conversion formulae from reported means (M) to give days of use in the past 30 days:.
1 % days used in past 90: M × 30.
2 Days used in past 60: M/2.
3 Days per week: (M/7) × 30.
4 Days used in past 90: M/3.
5 Days used in past 28: (M/28) × 30.
Table 1
Studies on treatment of cannabis use in the past 30 days within control groups of general populations: Studies reporting mean values.
Author (date) Sample
type
Basis of participation Disorder Country Control group Measure
Stephens et al. (2000) COM Wanting help quitting 98% current CUD US Delayed treatment # days used cannabis per month
Litt et al. (2005) COM Treatment 100% current CUD US Delayed treatment % days used cannabis in the past 90
Walker et al. (2006) SCH Information re their CU 68% current CUD
(86% lifetime CUD)
US Delayed treatment # days used cannabis in the past 60
Stephens et al. (2007) COM Feedback on CU (not treatment) 93% current CUD US Delayed feedback # days used cannabis per week
Martin and Copeland (2008) COM + OP Information, discussion 85% CUD AU Delayed treatment # days used cannabis in the past 90
Fischer et al. (2012) UNI …1 CU CAN General health
information
# days used cannabis in the past 30
Gates et al. (2012) COM Information or counselling on
CU concerns
98% probable CUD on SDS AU Delayed treatment # days used cannabis in the past 28
Rooke et al. (2013) COM Wanting to reduce or cease CU CU AU Cannabis information # days used cannabis in past month
AU: Australia; CAN: Canada; US: United States of America;
OP: Outpatients; COM: Community; HM: Homeless/unstably housed; SCH: School; UNI: University;
CU: Cannabis use; CUD: Cannabis use disorder (DSM-IIR or DSM-IV Cannabis Dependence or Abuse);
SDS: Severity of Dependence Scale (Gossop et al., 1992).
1 Mass advertising described the intervention study. Speciﬁc details on the basis of participation are not provided.
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tial samples.
Accordingly, the aim of the current paper was to determine the
degree of ‘natural recovery’ in the control groups from randomised
controlled trials on substance use disorders, which reported changes
in the frequency of cannabis use. ‘Natural recovery’ in this article refers
to processes where consumption of cannabis is reduced or ceased
without professional intervention. It was operationalised as the degree
of change in cannabis use within groups receiving inactive or minimal
interventions.
2. Methods
Electronic searches were performed in January 2015, to ﬁnd studies
that included a control group that had explored the topic of cannabis
use treatment. The search used title, abstract and keywords of Medline,
PsycINFO, Psychology Journals, and Psychology Subject Corner. The
search termswere: (cannabis ORmarijuana ORmarihuana OR addiction
OR abuse OR substance) AND (treatment OR randomi* control).
Potential studies were evaluated for inclusion in this study by the
ﬁrst author, based on whether they: (a) provided data on cannabis
use, which allowed the calculation of pre–post effect sizes in a group
of participants randomised to receive inactive (e.g. waitlist) or minimal
interventions (e.g. drug-related information only); (b) were in English;
(c) did not comprise case studies or personal accounts; (d) did not
include participants with severe mental disorders (i.e., schizophrenia,
bipolar disorder, posttraumatic stress disorder, major depressive disor-
der). In order to report results on a single measure, we restricted the
studies to those allowing a calculation of cannabis use in the previous
30 days.
The formal examination of effect sizes used Comprehensive
Meta-Analysis (Borenstein, Hedges, Higgins, & Rothstein, 2005),
and the primary analysis applied a random effects model. This is
the appropriate approach to use when samples or treatments are
potentially different, regardless of whether signiﬁcant heterogeneity is
evidenced (Borenstein, Hedges, Higgins, & Rothstein, 2009). We report
effects as standardisedmeandifferences (Cohen's d). Analyses of degree
of change require estimates of test–retest correlations of the measures,
or reported analyses of changes within groups. While Timeline
Followback assessments of cannabis use can have a 7–14 day test–retest
reliability of 0.92 (Robinson, Sobell, Sobell, & Leo, 2014), we do not
know the reliability of the 3–12 month assessments of cannabis use in
the current trials. We use an estimate of 0.70 for the primary analyses
below, but also undertake sensitivity analyses with test–retest correla-
tions of .60 and .80.Wheremeans and standard deviations were report-
ed on different sample sizes at baseline and follow-up, we used the
follow-up sample size for the analysis, estimating baseline scores forretained participants from reported data using the full sample. We
also present sample-weighted mean days of use at baseline, post and
follow-up assessments.
3. Results
The search of cannabis treatment in general population samples elic-
ited 2554 articles. Reviewing article titles to conﬁrm that they met the
search criteria left 374, and this numberwas reduced to 55 after reading
abstracts. Further searching using reference lists and cited reference
search yielded 12 potential articles, and 3 others were suggested by
reviewers. Review papers were examined (Carballo et al., 2007; Dutra
et al., 2008; Sobell, Ellingstad, & Sobell, 2000; Tanner-Smith, Wilson, &
Lipsey, 2013) to identify any additional papers, but none were added
from that procedure. A ﬁnal decision on inclusion was determined
after reading the full paper, and any that raised potential questions on
inclusion were reviewed by all authors, until consensus was reached.
Studies by Copeland et al. (2001), Lozano et al. (2006), Kadden et al.
(2007), Kay-Lambkin et al. (2009), Fernandes et al. (2010), Peters
et al. (2011), Stein et al. (2011), Walker et al. (2011), Litt et al. (2013)
and Hoch et al. (2014) were excluded due to an inability to calculate a
within-group effect size on cannabis use per month from the data
provided. The control groups of Stephens et al. (1994), Hendriks et al.
(2011) and Budney et al. (2000) provided too much support for them
to meet inclusion criteria as a control treatment condition.
Details of the eight included studies are displayed in Table 1, their re-
sults are provided in Table 2 and their methodological quality is
Table 3
Methodological review of control treatments from the included randomised controlled trials.
Study Symptom/diagnostic measure Treatment received by
controls
Follow-up
retention
Intention to treat (and
management of missing data)
Single-blind follow-up
Stephens et al. (2000) CUD: Self-report
CU: Self & collateral report
BL: No current formal treatment
4 mths: 6% had treatment
18% in self-help groups
92% to 4 mths No No—Self-report (phone
interview if no response)
Litt et al. (2005) CUD: SCID
CU: TLFB, Self & collateral
report, urinalysis.
BL: No current Mj therapy,
self-help group
4 mths: NR
93% to 4 mths No (Secondary analyses: BL
substitution)
No
Walker et al. (2006) CUD: GAIN
CU: Self-report
NR 98% to 3 mths No NR—Self-report; different
staff at follow-up
Stephens et al. (2007) CUD: SCID
CU: TLFB, self-report, urinalysis.
BL: No current Mj therapy,
self-help group
At 7-wks, 6 & 12 mths:
1–4% of whole sample in treatment
2–7% in self-help groups
97% at 7 wks Yes
(BL substitution. Checked with
imputation, omission)
No
Martin and Copeland
(2008)
CUD: Structured interview (GAIN)
& self-report (SDS)
CU: TLFB, self-report, urinalysis.
BL: No treatment in previous
90 days
3 mths: NR
80% at 3 mths Yes
(BL substitution)
NR (Independent
researcher)
Fischer et al. (2012) CU: Interviewer-administered
questionnaire
NR 52% at 12 mths No
Analysed completers of all
assessments
NR
Gates et al. (2012) Probable CUD: SDS
CU: TLFB, self-report.
BL: No current Mj therapy
3 mths: 46% sought treatment,
39% used medication
75% at 3 mths Yes
(Multiple imputation)
No
Rooke et al. (2013) CUD: GAIN
CU: TLFB, Self-report
BL: No formal Mj treatment in
last 3 mths
3 mths: Excluded 4% who had
treatment
66% at 6 wks
52% at 3 mths
No (Complier average causal effect
analyses. Checked with LOCF, omission)
Automated self-report
CU: Cannabis use; CUD: Cannabis Use Disorder;
SCID: Structured Interview for DSM-IV; GAIN: Global Appraisal of Individual Needs (Initial or ﬁnal) (Dennis, 1998, 1999);
TLFB: Timeline Follow-Back; SDS: Severity of Dependence Scale (Gossop et al., 1992);
LOCF: Last observation carried forward; BL: Baseline; Mj: Marijuana; NR: Not Reported.
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pants. Average weighted mean days of use in the previous 30 days fell
from 24.5 to 19.9 at 2–4 months across the eight studies. Only one of
the included studies (Fischer et al., 2012) provided data over a longer
follow-up, preventing an assessment of the degree of sustained change
across the studies. That study saw little change in use at 12 months
(M= 22.1, SD = 9.2).
Results of themeta-analysis using a test–retest correlation of .70 are
displayed in Fig. 1. The ﬁgure displays the average effect using a
ﬁxed-effects model.With a random effects model, there was an average
change in cannabis use of−.442 SD (CI:−.657 to−.228), which was
highly signiﬁcant (p b .001). A test of heterogeneity gave Q (7) =
57.71, p b .001, providing support for the selection of the random effects
model. Examination of the classic fail-safe N found that 293 missing
studies would be required to give p N .05. Sensitivity analyses using
random-effects models and test–retest correlations of .60 (−.460, CI:Fig. 1. Control group changes over 2–4−.685 to−.235) and .80 (−.415, CI:−.613 to−.217)made little differ-
ence to the result.
Four studies speciﬁcally targeted people who wanted to quit or
reduce cannabis use, or recruited them for an intervention trial
(Table 1). The remainder recruited people for information or discussion
about their cannabis use. Inspection of Fig. 1 shows that the latter group
included three of the four studies with weaker effects (Martin &
Copeland, 2008; Stephens et al., 2007; Walker et al., 2006), but it also
included the trial with the strongest effects (Gates et al., 2012).
An evaluation of the methodological quality of the control group
data is in Table 2. A strength of the studies was their follow-up rates
over the control period, with six having rates of 75% or above and four
having rates above 90%. None clearly had single-blind follow-up, but
two studies had an independent assessor conducting the follow-up,
and three used only self-report. Four studies checked participant reports
of cannabis use during follow-up against collateral data or urinalysis. Allmonths in non-psychotic groups.
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disorder, although only two used a gold-standard structured clinical
interview. A signiﬁcant potential threat to the interpretation of results
as being reﬂective of unassisted recovery was the lack of reports
on other concurrent treatment in four trials, and a high level of reported
treatment in one (Gates et al., 2012). Every study had at least one
signiﬁcant issue that should induce caution in the interpretation of its
results.
4. Discussion
Control groups from the eight randomised controlled trials showed a
signiﬁcant mean reduction in days of cannabis use. At 2–4 months'
follow up, participants used cannabis on 4.6 fewer days a month than
at baseline, reﬂecting over one additional day of abstinence each
week, and giving a total of more than a week of total abstinence each
month. The average effect size of−.415 to−.442 SD offers a challenging
base from which treatment effects are to be obtained. Our results will
assist in minimum sample size calculations for randomised controlled
trials, and provide a yardstick for the evaluation of changes from
services for cannabis misuse.
While we regard these self-initiated changes as substantial, they fall
short of major changes in sustained cessation, which supports the
contention that self-initiated cannabis cessation is difﬁcult. This obser-
vation is consistent with a comparison of reviews on placebo interven-
tions for different substances byMoore and Aubin (2012), which found
that nicotine provided the lowest abstinence rate (8%), followed by can-
nabis (15%) and alcohol (18%), with opioids (44%) and cocaine (47%)
providing the strongest responses. While the meta-review potentially
resulted inmultiple counting of trials and therewere few cannabis trials
in a single included review, the study highlighted the limited nature of
cannabis cessation rates, even in placebo conditions.
Interpretation of our results must be moderated by the issues raised
in our methodological review of the studies, which identiﬁed at least
one signiﬁcant limitation in every study. Perhaps most important was
the potential for other treatment to have been responsible for at least
some of the observed reductions in cannabis use. The results highlight
areas for future improvement of randomised controlled trials on
cannabis use disorder that will not only provide increased conﬁdence
in the estimates of change in control groups, but also in the reported
outcomes of the whole trial.
While there has been research into unassisted cessation of substance
misuse for more than 40 years (Carballo et al., 2007; Sobell et al., 2000),
it is only in the last 15 that this work has focused speciﬁcally on canna-
bis. To our knowledge, the current review is the ﬁrst to examine ‘natural
recovery’ in the control groups of randomised controlled trials. Regres-
sion to themeanmay account for some of the observed change, but our
results are consistent with population studies (Agosti & Levin, 2007;
Perkonnigg et al., 1999), which have similarly observed the potential
for recovery from both cannabis use and cannabis dependence, suggest-
ing that at least some individuals can reduce their cannabis usewithout
signiﬁcant help.
A limitation of this review was the fact that the initial literature
search relied on one author, although the resolution of any identiﬁed is-
sues and ﬁnal decisions on inclusion were by consensus of all authors,
and no additional papers were identiﬁed from reviews. Other limita-
tions included the small number of identiﬁed trials with control groups
that had no or minimal treatment, and the fact that minimal treatment
controls can typically be conducted for periods of only 2–4 months at
most. We excluded eight studies because of an absence of data on
cannabis consumption over a speciﬁc period, in order to preserve com-
parability of the results across studies: if those studies had provided
consumption data, we could potentially have doubled the number of
studies in our review. We recommend that future studies routinely
include both abstinence rates and average consumption data as part of
their results (Peters et al., 2011). However, despite the restrictednumber of studies, the total sample size of 600 provided a substantial
group for estimation of consumption changes.
5. Conclusions
This is the ﬁrst meta-analysis to explore changes in cannabis use in
control conditions of treatment studies. Results of the current study
demonstrate that modest average reductions in the frequency of
average cannabis use can be seen, although there was substantial
variability in effect size between studies, and some uncertainty over
the potential role of outside treatment in the effects. The study gives
weight to further exploration of the concept of natural recovery in
people with cannabis use disorders and provides researchers and
practitioners a baseline from which to estimate likely changes or needed
effects sizes in intervention studies.
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